Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Robert F H, Walter"'
Autor:
Sabrina Borchert, Alexander Mathilakathu, Alina Nath, Michael Wessolly, Elena Mairinger, Daniel Kreidt, Julia Steinborn, Robert F. H. Walter, Daniel C. Christoph, Jens Kollmeier, Jeremias Wohlschlaeger, Thomas Mairinger, Luka Brcic, Fabian D. Mairinger
Publikováno v:
International Journal of Molecular Sciences, Vol 24, Iss 15, p 12426 (2023)
The exact mechanism of desmoplastic stromal reaction (DSR) formation is still unclear. The interaction between cancer cells and cancer-associated fibroblasts (CAFs) has an important role in tumor progression, while stromal changes are a poor prognost
Externí odkaz:
https://doaj.org/article/e183de99799c44e0a585e5da333f4d6d
Autor:
Ramona Erber, Miriam Angeloni, Robert Stöhr, Michael P. Lux, Daniel Ulbrich-Gebauer, Enrico Pelz, Agnes Bankfalvi, Kurt W. Schmid, Robert F. H. Walter, Martina Vetter, Christoph Thomssen, Doris Mayr, Frederick Klauschen, Peter Sinn, Karl Sotlar, Katharina Stering, Albrecht Stenzinger, Marius Wunderle, Peter A. Fasching, Matthias W. Beckmann, Oliver Hoffmann, Rainer Kimmig, Nadia Harbeck, Rachel Wuerstlein, Fulvia Ferrazzi, Arndt Hartmann
Publikováno v:
International Journal of Molecular Sciences, Vol 23, Iss 15, p 8716 (2022)
In intermediate risk hormone receptor (HR) positive, HER2 negative breast cancer (BC), the decision regarding adjuvant chemotherapy might be facilitated by multigene expression tests. In all, 142 intermediate risk BCs were investigated using the PAM5
Externí odkaz:
https://doaj.org/article/aed511032752487bac880db052f7203c
Autor:
Sabrina Borchert, Michael Wessolly, Jan Schmeller, Elena Mairinger, Jens Kollmeier, Thomas Hager, Thomas Mairinger, Thomas Herold, Daniel C. Christoph, Robert F. H. Walter, Wilfried E. E. Eberhardt, Till Plönes, Jeremias Wohlschlaeger, Clemens Aigner, Kurt Werner Schmid, Fabian D. Mairinger
Publikováno v:
BMC Cancer, Vol 19, Iss 1, Pp 1-12 (2019)
Abstract Background Malignant pleural mesothelioma (MPM) is a tumour arising from pleural cavities with poor prognosis. Multimodality treatment with pemetrexed combined with cisplatin shows unsatisfying response-rates of 40%. The reasons for the rath
Externí odkaz:
https://doaj.org/article/a78dfbb5af2449eea6d8fb6a3f276409
Autor:
Luka Brcic, Alexander Mathilakathu, Robert F. H. Walter, Michael Wessolly, Elena Mairinger, Hendrik Beckert, Daniel Kreidt, Julia Steinborn, Thomas Hager, Daniel C. Christoph, Jens Kollmeier, Thomas Mairinger, Jeremias Wohlschlaeger, Kurt Werner Schmid, Sabrina Borchert, Fabian D. Mairinger
Publikováno v:
Cancers, Vol 13, Iss 8, p 1761 (2021)
Malignant pleural mesothelioma (MPM) is an aggressive malignancy associated with asbestos exposure. Median survival ranges from 14 to 20 months after initial diagnosis. As of November 2020, the FDA approved a combination of immune checkpoint inhibito
Externí odkaz:
https://doaj.org/article/82f5093821024d11aa5c105a11b297b7
Autor:
Michael, Wessolly, Susann, Stephan-Falkenau, Anna, Streubel, Robert, Werner, Sabrina, Borchert, Sergej, Griff, Elena, Mairinger, Robert F H, Walter, Torsten, Bauer, Wilfried E E, Eberhardt, Torsten G, Blum, Kurt W, Schmid, Jens, Kollmeier, Thomas, Mairinger, Fabian D, Mairinger
Publikováno v:
Cancer Management and Research
Background Immune checkpoint inhibition, especially the blockade of PD-1 and PD-L1, has become one of the most thriving therapeutic approaches in modern oncology. Immune evasion caused by altered tumor epitope processing (so-called processing escapes